Improvement of quality of life in patients with chronic inflammatory demyelinating polyneuropathy shifting from 16 to 20% subcutaneous immunoglobulins

Neurol Sci. 2013 Nov;34(11):2061-2. doi: 10.1007/s10072-013-1426-5. Epub 2013 Apr 11.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Immunoglobulins / administration & dosage*
  • Immunoglobulins / therapeutic use
  • Immunologic Factors / administration & dosage*
  • Immunologic Factors / therapeutic use
  • Infusions, Subcutaneous
  • Male
  • Middle Aged
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / drug therapy*
  • Quality of Life*
  • Young Adult

Substances

  • Immunoglobulins
  • Immunologic Factors